Las Condes 26 02

85 / 140

207
[FARMACOGENÓMICA: APLICACIONES CARDIOVASCULARES -Luis Quiñones S. Ph.D. y cols.]
7. Silva H, Hernandez-Hernandez R, Vinueza R, Velasco M, Boissonnet
CP, Escobedo J, et al. Cardiovascular risk awareness, treatment,
and control in urban Latin America. Am J Ther. Jan;17:159–66.
8. MINSAL. Estrategia Nacional de Salud 2011-2020 [Internet].
2011. Available from:
c4034eddbc96ca6de0400101640159b8.pdf
9. MINSAL. Objetivos Sanitarios de la década 2000-2010.
Evaluación final del período. 2010.
10. MINSAL. Aprueba Garantias Explicitas de Salud del Regimen
General de Garantias Explicitas en Salud. Decreto No1, 6.01.2010.
Publicado en el Diario oficial el 27.02.2010. 2010.
11. MINSAL. Implementacion del Enfoque de Riesgo en el Programa Salud
Cardiovascular [Internet]. 2009 [cited 2015 Jan 16]. Available
from:
12. MINSAL. Estrategia para la Reduccion del Consumo de Sal en Chile.
Departamento de Alimentos y Nutricion. Division de Politicas
Publicas Saludables y Promocion. 2010.
13. MINSAL. Norma Tecnica de Vigilancia de Enfermedades No
Transmisibles y sus Factores de Riesgo. Departamento de
Epidemiologia, División de Planificación Sanitaria [Internet].
2011. Available from:
vent/NormaTecnicaVENT.pdf.
14. MINSAL. Hipertensión Arterial Primaria o Esencial en
personas de 15 años y más.Hipertensión Arterial Primaria
o Esencial en personas de 15 años y más [Internet]. 2010.
p. 27–47. Available from:
item/7220fdc4341c44a9e04001011f0113b9.pdf
15. Zhou S, Di Y, Chan E, Du Y, Chow V, Xue C, et al. Clinical
pharmacogenetics and potential application in personalized
medicine. Curr Drug Metab. 2008;9:738–84.
16. Wilkinson G. Drug metabolism and variability among patients in
drug response. N Engl J Med. 2005;352:2211–21.
17. Xie H-G, Frueh F. Pharmacogenomics steps toward personalized
medicine. Per Med. 2005;2:325–37.
18. Wijnen P, Op den Buijsch R, Drent M, Kuijpers P, Kuipers P, Neef C,
et al. The prevalence and clinical relevance of cytochrome P450
polymorphisms. Aliment Pharmacol Ther. 2007;26:211–9.
19. Evans W, McLeod H. Pharmacogenomics-drug disposition, drug
targets, and side effects. N Engl J Med. 2003;348:538–49.
20. Vesell E. Advances in pharmacogenetics and pharmacogenomics. J
Clin Pharmacol. 2000;40:930–8.
21. Johnson J, Cavallari L. Pharmacogenetics and cardiovascular
disease-implications for personalized medicine. Pharmacol Rev.
2013;65:987–1009.
22. Smith N, Felix J, Morrison A, Demissie S, Glazer N, Loehr L, et al.
Association of genome-wide variation with the risk of incident
heart failure in adults of European and African ancestry: a
prospective meta-analysis from the cohorts for heart and aging
research in genomic epidemiology (CHARGE) consortium. Circ
Cardiovasc Genet. 2010;3:256–66.
23. Schunkert H, König I, Kathiresan S, Reilly M, Assimes T, Holm H, et al.
Large-scale association analysis identifies 13 new susceptibility
loci for coronary artery disease. Nat Genet. 2011;43:333–8.
24. Ellinor P, Lunetta K, Albert C, Glazer N, Ritchie M, Smith A, et al.
Meta-analysis identifies six new susceptibility loci for atrial
fibrillation. Nat Genet. 2012;44:670–5.
25. Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L, et al. Influence of
CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic
complications in warfarin-treated patients: a systematic review
and meta-analysis. Int J Cardiol. 2013;168:4234–43.
26. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al.
SLCO1B1 variants and statin-induced myopathy-a genomewide
study. N Engl J Med. 2008;359:789–99.
27. Kääb S, Crawford D, Sinner M, Behr E, Kannankeril P, Wilde A, et
al. A large candidate gene survey identifies the KCNE1 D85N
polymorphism as a possible modulator of drug-induced torsades
de pointes. Circ Cardiovasc Genet. 2012;5:91–9.
28. Roden D. Cardiovascular pharmacogenomics: the future of
cardiovascular therapeutics? Can J Cardiol. 2013;29:58–66.
29. Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomazic J, et
al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl
J Med. 2008;358:568–79.
30. Johnson J, Gong L, Whirl-Carrillo M, Gage B, Scott S, Stein C, et
al. Clinical Pharmacogenetics Implementation Consortium
Guidelines for CYP2C9 and VKORC1 genotypes and warfarin
dosing. Clin Pharmacol Ther. 2011;90:625–9.
31. Gadisseur A, van der Meer F, Adriaansen H, Fihn S, Rosendaal
F. Therapeutic quality control of oral anticoagulant therapy
comparing the short-acting acenocoumarol and the long-acting
phenprocoumon. Br J Haematol. 2002;117:940–6.
32. Ufer M. Comparative pharmacokinetics of vitamin K antagonists:
warfarin, phenprocoumon and acenocoumarol. Clin
Pharmacokinet. 2005;44:1227–46.
33. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo
N, et al. A genome-wide association study confirms VKORC1,
CYP2C9, and CYP4F2 as principal genetic determinants of
warfarin dose. PLoS Genet. 2009;5:e1000433.
34. Lee M, Klein T. Pharmacogenetics of warfarin: challenges and
opportunities. J Hum Genet. 2013;58:334–8.
35. Wang D, Chen H, Momary KM, Cavallari L, Johnson J, Sadée W.
Regulatory polymorphism in vitamin K epoxide reductase complex
subunit 1 (VKORC1) affects gene expression and warfarin dose
requirement. Blood. 2008;112:1013–21.
36. Reitsma P, van der Heijden J, Groot A, Rosendaal F, Büller H. A
C1173T dimorphism in the VKORC1 gene determines coumarin
sensitivity and bleeding risk. PLoS Med. 2005;2:e312.
37. Markatos C, Grouzi E, Politou M, Gialeraki A, Merkouri E, Panagou I,
et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol
dose requirements in Greek patients. Pharmacogenomics.
2008;9:1631–8.
38. Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T,
Haltmayer M, et al. Genetic determinants of acenocoumarol
and phenprocoumon maintenance dose requirements. Eur J Clin
Pharmacol. 2010;66:253–60.
39. Kovac M, Maslac A, Rakicevic L, Radojkovic D. The c.-1639G>A
polymorphism of the VKORC1 gene in Serbian population:
retrospective study of the variability in response to oral anticoagulant
therapy. Blood Coagul Fibrinolysis. 2010;21:558–63.